Abstract 50P
Background
Papillary thyroid carcinoma (PTC) has a specific integrin expression signature that correlates with histopathology, specific driver gene mutations, and aggressiveness of the disease. α3β1 integrin is overexpressed, it is involved in PTC cell motility and invasion and is associated with an advanced disease and a worst outcome. Histopathology studies indicate that fibronectin 1 (FN1) and its integrin ligand αVβ3 are overexpressed in PTC. In normal thyroid cells, fibronectin (FN) stimulates DNA synthesis, proliferation and survival through αVβ3 binding.
Methods
The mRNA expression of integrins and FN1 genes in normal thyroid tissues and PTC were assessed in the TCGA database. -The level of FN and αVβ3 in was assessed by immunofluorescence in PTC cell lines (BCPAP, K1) and in a normal thyroid cell line (Nthy-ori3-1). -The release and deposition of FN were estimated by enzyme-linked immunoassay. - The proliferation was measured by MTT assay. -The silencing of gene FN1 in the K1 cell line was performed with KN2.0, non-homology mediated CRISPR knockout kit (ORIGENE®).
Results
Analysis of the TCGA database on 402 PTC and 82 healthy tissues demonstrates that FN1 mRNA is 60 times more expressed in PTC than in healthy tissue and that the ITGAV and ITGB1 subunits are more expressed. The increase in FN1 and ITGAV mRNA expression is associated with metastatic lymph nodes, more advanced staging, extrathyroidal extension, and higher risk. PTC cells show higher expression of integrin αVβ3, the main receptor of FN1 and at the same time a high production of fibronectin. The gene FN1 was silenced in K1 cell line (K1FN1-/-). Both K1 and K1FN1-/- seeded in collagen coated plates attached and survived in the absence of serum. While K1 proliferated under these culture conditions, proliferation was almost absent in K1FN1-/- and was rescued by soluble FN.
Conclusions
Papillary thyroid carcinoma cells express high amounts of αVβ3 integrin and produce more fibronectin. - Fibronectin/ αVβ3 interaction could be a mechanism of disease progression in PTC. - Fibronectin can be a powerful prognostic indicator and a site of pharmacological intervention.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
University of Salerno.
Funding
Department of Medicine, Surgery and Dentistry, University of Salerno.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
95P - Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing
Presenter: Giorgia Bortolus
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Physician perceptions and the evolving landscape of next generation sequencing (NGS) use across EU4+UK
Presenter: Keerun Khela
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)
Presenter: Phoebe Cheng
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Clinical implementation of NGS and ESCAT for optimized cancer therapy
Presenter: AI. Martin-Quesada
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Prevalence of homologous recombination repair deficiency-associated variants in non-selected Portuguese patients with metastatic prostate cancer
Presenter: Tiago Barroso
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany
Presenter: Maike Collienne
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Molecular tumor board for advanced cancer patients offers new therapeutic opportunities beyond level 1 ESCAT scale
Presenter: Victor Segui-Manzaneque
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - NICE recommendations and ESMO-MCBS/ESCAT scores for solid tumour drugs
Presenter: Eunice Xing
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Comprehensive analysis of clinical characteristics and germline status among colorectal cancer patients in a tertiary care center in Thailand
Presenter: NUTDANAI ROILA
Session: Cocktail & Poster Display session
Resources:
Abstract